RU2019100887A - Композиции антитела и белка - Google Patents

Композиции антитела и белка Download PDF

Info

Publication number
RU2019100887A
RU2019100887A RU2019100887A RU2019100887A RU2019100887A RU 2019100887 A RU2019100887 A RU 2019100887A RU 2019100887 A RU2019100887 A RU 2019100887A RU 2019100887 A RU2019100887 A RU 2019100887A RU 2019100887 A RU2019100887 A RU 2019100887A
Authority
RU
Russia
Prior art keywords
antibody
salt
protein
composition
free
Prior art date
Application number
RU2019100887A
Other languages
English (en)
Other versions
RU2019100887A3 (ru
Inventor
Синхан МА
Юнь СЯН
Original Assignee
Байер Хелскеа Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/601,598 external-priority patent/US8613919B1/en
Application filed by Байер Хелскеа Ллк filed Critical Байер Хелскеа Ллк
Publication of RU2019100887A publication Critical patent/RU2019100887A/ru
Publication of RU2019100887A3 publication Critical patent/RU2019100887A3/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (36)

1. Свободная от соли композиция белка или антитела, включающая:
a. гистидин;
b. неионный поверхностно-активный агент;
c. сахар или сахарный спирт, выбранный из маннита, декстрозы, глюкозы, трегалозы и сахарозы;
d. аргинин;
e. лизин;
f. глицин или аланин;
g. метионин; и
h. белок или антитело;
где указанная композиция белка или антитела имеет значение рН, которое колеблется от рН 4,0 до рН 6,0 и где указанная композиция белка существенно не содержит неорганической соли.
2. Свободная от соли композиция белка или антитела по п. 1, где указанная композиция имеет вязкость, которая колеблется от 1 до 8 мПа⋅с при 22°С.
3. Свободная от соли композиция белка или антитела по п. 1, где указанная композиция имеет осмоляльность, которая колеблется от 240 до 380 ммоль/кг.
4. Свободная от соли композиция белка или антитела по п. 1, где указанный неионный поверхностно-активный агент представляет собой полисорбат, выбранный из полисорбата 20 и полисорбата 80.
5. Свободная от соли композиция белка или антитела по п. 1, где указанный сахар представляет собой сахарозу.
6. Свободная от соли композиция белка или антитела по п. 1, включающая от 10 мМ до 50 мМ аргинина.
7. Свободная от соли композиция белка или антитела по п. 1, включающая от 5 мМ до 10 мМ метионина.
8. Свободная от соли композиция антитела к TFPI, включающая:
a. гистидин,
b. неионный поверхностно-активный агент,
c. сахар или сахарный спирт, выбранный из маннита, декстрозы, глюкозы, трегалозы и сахарозы,
d. аргинин,
e. лизин,
f. глицин или аланин,
g. метионин, и
h. антитело к TFPI;
где указанная композиция антитела к TFPI имеет значение рН от рН 4,0 до рН 6,0 и где указанная композиция антитела к TFPI существенно не содержит неорганической соли.
9. Свободная от соли композиция антитела к TFPI по п. 8, где указанная композиция имеет значение вязкости, которое колеблется от 1 до 8 мПа⋅с при 22°С.
10. Свободная от соли композиция антитела к TFPI по п. 8, где указанная композиция имеет осмоляльность, которая колеблется от 240 до 380 ммоль/кг.
11. Свободная от соли композиция антитела к TFPI по п. 8, где указанный неионный поверхностно-активный агент представляет собой полисорбат, выбранный из полисорбата 20 и полисорбата 80.
12. Свободная от соли композиция антитела к TFPI по п. 8, где указанный сахар представляет собой сахарозу.
13. Свободная от соли композиция антитела к TFPI по п. 8, где указанное антитело к TFPI представляет собой человеческое IgG2 моноклональное антитело.
14. Свободная от соли композиция антитела к TFPI по п. 8, где указанное человеческое IgG2 моноклональное антитело содержит легкую цепь, включающую аминокислотную последовательность SEQ ID NO: 1, и тяжелую цепь, включающую аминокислотную последовательность SEQ ID NO: 2.
15. Способ лечения расстройства у пациента, где указанный способ включает введение указанному пациенту терапевтически эффективного количества композиции белка или антитела, включающей гистидин, полисорбат 80 или полисорбат 20, сахарозу, аргинин, лизин, глицин, метионин и белок или антитело при значении рН от рН 4,0 до рН 6,0, где указанная композиция белка или антитела существенно не содержит неорганической соли.
16. Способ по п. 15, где указанная композиция белка или антитела вводится внутривенно, подкожно или внутримышечно.
17. Способ по п. 15, где указанный белок или антитело представляет собой человеческое моноклональное антитело к TFPI.
18. Способ по п. 17, где указанное человеческое моноклональное антитело содержит легкую цепь, включающую аминокислотную последовательность SEQ ID NO: 1, и тяжелую цепь, включающую аминокислотную последовательность SEQ ID NO: 2.
RU2019100887A 2012-08-31 2013-08-28 Композиции антитела и белка RU2019100887A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13/601,598 2012-08-31
US13/601,598 US8613919B1 (en) 2012-08-31 2012-08-31 High concentration antibody and protein formulations
US13/843,780 2013-03-15
US13/843,780 US9592297B2 (en) 2012-08-31 2013-03-15 Antibody and protein formulations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2015111341A Division RU2678097C2 (ru) 2012-08-31 2013-08-28 Композиции антитела и белка

Publications (2)

Publication Number Publication Date
RU2019100887A true RU2019100887A (ru) 2019-03-22
RU2019100887A3 RU2019100887A3 (ru) 2019-08-27

Family

ID=49162239

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2019100887A RU2019100887A (ru) 2012-08-31 2013-08-28 Композиции антитела и белка
RU2015111341A RU2678097C2 (ru) 2012-08-31 2013-08-28 Композиции антитела и белка

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2015111341A RU2678097C2 (ru) 2012-08-31 2013-08-28 Композиции антитела и белка

Country Status (26)

Country Link
US (7) US9592297B2 (ru)
EP (3) EP2890718A1 (ru)
JP (3) JP6462567B2 (ru)
CN (2) CN114392353A (ru)
AR (2) AR092388A1 (ru)
AU (3) AU2013308902B2 (ru)
BR (1) BR112015003838A2 (ru)
CA (2) CA2883095C (ru)
CY (1) CY1121989T1 (ru)
DK (1) DK3117837T3 (ru)
ES (1) ES2741575T3 (ru)
HK (1) HK1210794A1 (ru)
HR (1) HRP20191299T1 (ru)
HU (1) HUE045652T2 (ru)
IL (6) IL294567A (ru)
LT (1) LT3117837T (ru)
MX (2) MX369653B (ru)
PL (1) PL3117837T3 (ru)
PT (1) PT3117837T (ru)
RS (1) RS59221B1 (ru)
RU (2) RU2019100887A (ru)
SG (2) SG11201501116RA (ru)
SI (1) SI3117837T1 (ru)
TW (4) TW201825116A (ru)
UY (1) UY34995A (ru)
WO (1) WO2014036071A1 (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47150E1 (en) 2010-03-01 2018-12-04 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
HUE042706T2 (hu) * 2011-04-01 2019-07-29 Bayer Healthcare Llc Monoklonális ellenanyagok szövetifaktorút-inhibitor (TFPI) ellen
AT512589B1 (de) * 2012-03-12 2014-06-15 Zizala Lichtsysteme Gmbh Lichtleitelement für einen Laser-Fahrzeugscheinwerfer sowie Fahrzeugscheinwerfer
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
WO2015038811A2 (en) 2013-09-11 2015-03-19 Arsia Therapeutics, Inc. Liquid protein formulations containing ionic liquids
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US9982061B2 (en) 2014-10-01 2018-05-29 Medimmune Limited Antibodies to ticagrelor and methods of use
JP6716577B2 (ja) 2014-10-01 2020-07-01 イーグル・バイオロジクス・インコーポレイテッドEagle Biologics, Inc. 粘度低下物質を含有する、多糖および核酸の調合薬
KR102068915B1 (ko) 2015-08-19 2020-01-22 화이자 인코포레이티드 조직 인자 경로 억제제 항체 및 그의 용도
CN107921109A (zh) 2015-08-19 2018-04-17 阿斯利康(瑞典)有限公司 稳定的抗ifnar1配制品
AU2016329034B2 (en) * 2015-09-22 2019-05-23 Pfizer Inc. Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method
EP3443346B1 (en) * 2016-04-13 2023-08-30 Medimmune, LLC Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
JOP20180125B1 (ar) 2016-06-30 2022-09-15 Celltrion Inc صيغة صيدلانية سائلة ثابتة
US10279048B2 (en) 2016-07-13 2019-05-07 Reform Biologics, Llc Stabilizing excipients for therapeutic protein formulations
CA3036965A1 (en) 2016-09-16 2018-03-22 Leukocare Ag A method for stabilization of a biopharmaceutical drug product during processing
GEP20237513B (en) * 2016-12-23 2023-06-12 Serum Institute Of India Pvt Ltd Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
EP3618871A4 (en) 2017-05-02 2021-01-06 Merck Sharp & Dohme Corp. ANTI-LAG3 ANTIBODIES ETCO-FORMULATIONS ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
JOP20200275A1 (ar) 2018-05-10 2020-11-02 Regeneron Pharma صيغ تحتوي على بروتين اندماج لمستقبلvegf مرتفعة التركيز
JP2021529800A (ja) * 2018-07-05 2021-11-04 バイエル アクチェンゲゼルシャフトBayer Aktiengesellschaft 抗FXIa抗体のための新規な安定した高濃度製剤
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
JP7467438B2 (ja) * 2018-10-18 2024-04-15 メルク・シャープ・アンド・ドーム・エルエルシー 抗rsv抗体の製剤及びその使用方法
CN111346225A (zh) * 2018-12-21 2020-06-30 上海张江生物技术有限公司 含有蛋白质的药物制剂
CN114786717A (zh) * 2019-11-13 2022-07-22 辉瑞公司 稳定的水性抗-tfpi抗体制剂
WO2024026388A1 (en) * 2022-07-27 2024-02-01 Viela Bio, Inc. Formulations comprising an immunoglobulin-like transcript 7 (ilt7)-binding protein

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1064396A (en) 1975-02-18 1979-10-16 Myer L. Coval Fractional precipitation of gamma globulin with polyethylene glycol
US4075193A (en) 1976-11-26 1978-02-21 Parke, Davis & Company Process for producing intravenous immune globulin
US4374763A (en) 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
US4499073A (en) 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
EP0303746B2 (en) 1987-08-21 1998-12-02 Mallinckrodt Group Inc. Stabilization of growth promoting hormones
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US4912861A (en) * 1988-04-11 1990-04-03 Huang Ing Chung Removable pressure-adjustable shock-absorbing cushion device with an inflation pump for sports goods
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
EP0417193B1 (en) 1988-05-27 1993-08-04 Centocor, Inc. Freeze-dried formulation for antibody products
CA2049342A1 (en) 1989-03-27 1990-09-28 Sally Bolmer Formulations for stabilizing of igm antibodies
US5217954A (en) 1990-04-04 1993-06-08 Scios Nova Inc. Formulations for stabilizing fibroblast growth factor
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
US6165467A (en) 1991-07-20 2000-12-26 Yoshihide Hagiwara Stabilized human monoclonal antibody preparation
JP2966592B2 (ja) 1991-07-20 1999-10-25 萩原 義秀 安定化されたヒトモノクローナル抗体製剤
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
US5849700A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
ES2153418T3 (es) 1993-02-23 2001-03-01 Genentech Inc Estabilizacion de polipeptidos tratados con solventes organicos por medio de excipientes.
DE4344824C1 (de) 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
GB9418092D0 (en) 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
ES2435462T3 (es) 1995-07-27 2013-12-19 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6686191B1 (en) 1995-09-22 2004-02-03 Bayer Healthcare Llc Preparation of virally inactivated intravenously injectable immune serum globulin
SK101398A3 (en) 1996-01-25 1998-12-02 Schering Ag Improved concentrated injection and infusion solutions for intravenous administration
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
KR100236393B1 (ko) 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
TWI240627B (en) 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
CA2302708A1 (en) 1997-08-21 1999-03-04 Siemens Aktiengesellschaft Method for transmitting user data that can be allocated to different applications
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
BR0014486A (pt) 1999-10-04 2002-09-17 Chiron Corp Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado
WO2001064241A1 (fr) 2000-02-29 2001-09-07 Chugai Seiyaku Kabushiki Kaisha Preparations stabilisees a long terme
DE60128793T2 (de) 2000-04-07 2008-02-07 Signal Coordinating Therapy Inc. Verfahren und Zusammensetzung zur Behandlung von Neoplasmen
EP1336410A4 (en) 2000-08-04 2005-10-12 Chugai Pharmaceutical Co Ltd PROTEIN INJECTION PREPARATIONS
US8632778B2 (en) 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
CN1204921C (zh) 2000-09-01 2005-06-08 中外制药株式会社 长期稳定溶液制剂
PT1324776E (pt) 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
JP4317010B2 (ja) * 2001-07-25 2009-08-19 ピーディーエル バイオファーマ,インコーポレイティド IgG抗体の安定な凍結乾燥医薬製剤
AU2002335815A1 (en) 2001-10-16 2003-04-28 Rxkinetix, Inc. High-concentration protein formulations and method of manufacture
CN1292655C (zh) 2001-11-08 2007-01-03 蛋白质设计实验室股份有限公司 IgG抗体稳定的液态药物制剂
US20030138416A1 (en) 2001-12-03 2003-07-24 Jesper Lau Use of glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
AU2002351353A1 (en) 2001-12-19 2003-09-02 Genentech, Inc. Stabilizing polypeptides which have been exposed to urea
DK1475101T3 (da) 2002-02-14 2011-01-10 Chugai Pharmaceutical Co Ltd Antistof-holdige farmaceutiske opløsninger
JP4583762B2 (ja) 2002-02-27 2010-11-17 イミュネックス・コーポレーション ポリペプチド製剤
AU2005254062B2 (en) 2002-04-11 2011-02-17 Medimmune, Llc High pressure spray-dry of bioactive materials
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040022792A1 (en) 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
NZ537687A (en) 2002-06-21 2008-04-30 Biogen Idec Inc Buffered formulations for concentrating antibodies and methods of use thereof
WO2004007520A2 (en) 2002-07-12 2004-01-22 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
JP4584713B2 (ja) 2002-10-08 2010-11-24 ライナット ニューロサイエンス コーポレイション 神経成長因子アンタゴニストを投与することによって術後疼痛を処置するための方法および神経成長因子アンタゴニストを含有する組成物
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
DK1575517T3 (da) 2002-12-24 2012-05-14 Rinat Neuroscience Corp Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
ZA200507757B (en) 2003-04-04 2007-01-31 Genentech Inc High concentration antibody and protein formulations
NZ599196A (en) 2003-07-15 2014-01-31 Amgen Inc Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
PL1698640T5 (pl) 2003-10-01 2019-12-31 Kyowa Hakko Kirin Co., Ltd. Sposób stabilizacji przeciwciała i stabilizowany preparat przeciwciała w postaci roztworu
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
EP1712240B1 (en) 2003-12-25 2015-09-09 Kyowa Hakko Kirin Co., Ltd. Stable water-based medicinal preparation containing antibody
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
AU2006207901A1 (en) 2005-01-28 2006-08-03 Wyeth Stabilized liquid polypeptide formulations
CA2600608A1 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Composition comprising human igg2 antibody and chelating agent
EP1858928A2 (en) 2005-03-08 2007-11-28 Pharmacia & Upjohn Company LLC Anti-m-csf antibody compositions having reduced levels of endotoxin
ES2407468T3 (es) * 2005-04-18 2013-06-12 Yeda Research And Development Company Limited Formulaciones de anticuerpos anti-hepatitis B (HBV) estabilizadas
WO2007002543A2 (en) * 2005-06-23 2007-01-04 Medimmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
DK1899462T3 (da) 2005-07-02 2011-06-06 Arecor Ltd Stabile vandige systemer omfattende proteiner
NZ564843A (en) 2005-08-03 2012-05-25 Immunogen Inc Immunoconjugate formulations comprising an immunoconjugate and an excipient in a buffered aqueous solution
AU2006295340B2 (en) 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
CN101360821A (zh) 2005-11-21 2009-02-04 圣诺菲·帕斯图尔有限公司 重组病毒的稳定制剂
WO2007074880A1 (ja) 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
CA2638811A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
DE102006005094A1 (de) 2006-02-04 2007-08-09 Degussa Gmbh Titandioxid und Polycarboxylatether enthaltende Dispersion
WO2007147001A2 (en) 2006-06-14 2007-12-21 Imclone Systems Incorporated Lyophilized formulations of anti-egfr antibodies
DK2426150T3 (en) 2006-06-30 2018-01-22 Novo Nordisk As ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF
CN101522219A (zh) 2006-10-12 2009-09-02 惠氏公司 改变抗体溶液中离子强度以减少乳光/聚集物
RU2009126420A (ru) * 2006-12-11 2011-01-20 Ф.Хоффманн-Ля Рош Аг (Ch) Парентеральная лекарственная форма антитела к абета
EP2703007A1 (en) 2007-03-30 2014-03-05 MedImmune, LLC Antibodies with decreased deamidation profiles
GB0707938D0 (en) 2007-04-25 2007-05-30 Univ Strathclyde Precipitation stabilising compositions
AU2008266051B2 (en) 2007-06-14 2014-07-31 Biogen Ma Inc. Antibody formulations
AU2008269086B2 (en) * 2007-06-25 2014-06-12 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
WO2009070642A1 (en) 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation
RU2563343C2 (ru) 2007-12-14 2015-09-20 Ново Нордиск А/С Антитела к человеческому nkg2d и их применения
CN105126099A (zh) * 2007-12-21 2015-12-09 弗·哈夫曼-拉罗切有限公司 抗体制剂
RU2470628C2 (ru) 2007-12-28 2012-12-27 Биоинвент Интернешнл Аб Состав
BRPI0907532A2 (pt) 2008-02-20 2015-07-28 G2 Inflammation Pty Ltd Anticorpos anti-c5ar humanizados
WO2009120684A1 (en) 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
EP2297203A1 (en) 2008-06-30 2011-03-23 Novo Nordisk A/S Anti-human interleukin-20 antibodies
UA112050C2 (uk) 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
TR201802935T4 (tr) 2008-09-19 2018-03-21 Pfizer Stabil sıvı antikor formülasyonu.
JP2012510468A (ja) 2008-11-28 2012-05-10 アボット・ラボラトリーズ 安定な抗体組成物およびこれを安定させるための方法
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
DK2379600T4 (da) 2008-12-22 2021-01-04 Novo Nordisk As Antistoffer mod tissue factor pathway inhibitor
AU2010221156A1 (en) 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
JP2012530721A (ja) 2009-06-18 2012-12-06 ワイス・エルエルシー 小モジュール免疫薬のための凍結乾燥製剤
EP2473527B1 (en) 2009-09-03 2016-11-30 Ablynx N.V. Stable formulations of polypeptides and uses thereof
EP2332995A1 (en) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
SI3409289T1 (sl) 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
USRE47150E1 (en) 2010-03-01 2018-12-04 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
WO2011108452A1 (ja) * 2010-03-02 2011-09-09 Jnc株式会社 還元反応器
EP2547355B1 (en) * 2010-03-19 2017-01-11 Baxalta GmbH Tfpi inhibitors and methods of use
BR112012030139A2 (pt) 2010-05-28 2017-06-13 Novo Nordisk As composições estáveis de anticorpos de doses múltiplas compreendendo um anticorpo e um preservante
JP5918246B2 (ja) * 2010-10-06 2016-05-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. 抗インターロイキン−4受容体(il−4r)抗体を含有する安定化製剤
HUE042706T2 (hu) 2011-04-01 2019-07-29 Bayer Healthcare Llc Monoklonális ellenanyagok szövetifaktorút-inhibitor (TFPI) ellen
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) * 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations

Also Published As

Publication number Publication date
PT3117837T (pt) 2019-08-26
CY1121989T1 (el) 2020-10-14
CA2883095C (en) 2021-10-26
TW201927338A (zh) 2019-07-16
HK1210794A1 (en) 2016-05-06
IL279237A (en) 2021-01-31
ES2741575T3 (es) 2020-02-11
CN114392353A (zh) 2022-04-26
MX2015002411A (es) 2015-06-05
IL294567A (en) 2022-09-01
AR092400A1 (es) 2015-04-22
US9592297B2 (en) 2017-03-14
WO2014036071A1 (en) 2014-03-06
US20210077381A1 (en) 2021-03-18
JP2019048886A (ja) 2019-03-28
TWI609697B (zh) 2018-01-01
MX369653B (es) 2019-11-15
RU2015111341A (ru) 2016-10-27
AU2018203320B2 (en) 2020-02-27
DK3117837T3 (da) 2019-08-19
AU2013308902B2 (en) 2018-04-12
CA3129277A1 (en) 2014-03-06
JP2015528464A (ja) 2015-09-28
IL286784A (en) 2021-10-31
IL237188A0 (en) 2015-04-30
RS59221B1 (sr) 2019-10-31
JP6462567B2 (ja) 2019-01-30
EP2890718A1 (en) 2015-07-08
EP3590536A1 (en) 2020-01-08
TW201424748A (zh) 2014-07-01
US20180028669A1 (en) 2018-02-01
IL265864B (en) 2020-02-27
BR112015003838A2 (pt) 2017-07-04
LT3117837T (lt) 2019-09-25
AU2020200134A1 (en) 2020-01-30
AU2013308902A1 (en) 2015-03-12
EP3117837B1 (en) 2019-05-22
CN104684933A (zh) 2015-06-03
HUE045652T2 (hu) 2020-01-28
MX2019013670A (es) 2020-01-15
CN104684933B (zh) 2021-11-30
US20230190637A9 (en) 2023-06-22
US20150030591A1 (en) 2015-01-29
PL3117837T3 (pl) 2020-02-28
SI3117837T1 (sl) 2019-10-30
AU2018203320A1 (en) 2018-05-31
TW201414496A (zh) 2014-04-16
RU2019100887A3 (ru) 2019-08-27
US20180055940A1 (en) 2018-03-01
CA2883095A1 (en) 2014-03-06
US9849181B2 (en) 2017-12-26
IL265864A (en) 2019-06-30
TW201825116A (zh) 2018-07-16
US20140065159A1 (en) 2014-03-06
EP3117837A1 (en) 2017-01-18
HRP20191299T1 (hr) 2019-10-18
UY34995A (es) 2014-03-31
AR092388A1 (es) 2015-04-22
SG10201708215YA (en) 2017-11-29
SG11201501116RA (en) 2015-04-29
IL286784B (en) 2022-08-01
IL265865A (en) 2019-06-30
US20150209431A1 (en) 2015-07-30
JP2021059602A (ja) 2021-04-15
RU2678097C2 (ru) 2019-01-23
US20140105892A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
RU2019100887A (ru) Композиции антитела и белка
RU2015111319A (ru) Препараты антитела к рецептору анти-пролактина
JP2016515515A5 (ru)
PE20200513A1 (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso
RU2015123476A (ru) Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения
RU2019138507A (ru) Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
RU2012131099A (ru) Препарат антитела
JP2019514998A5 (ru)
AR089787A1 (es) Formulaciones estabilizadas que contienen anticuerpos anti-ang2
UA107211C2 (uk) Стабілізовані склади, які містять антитіла до рецептора інтерлейкіну 6 (il-6r)
RU2012125254A (ru) Составы антитела
SI2331090T1 (en) Stable liquid antibody formulation
US20140044727A1 (en) Formulations with reduced viscosity
AR095496A1 (es) Formulaciones de anticuerpos anti-receptor de prolactina
JP2020509031A5 (ru)
RU2017107847A (ru) Стабильный состав на основе антитела к il-4r-альфа
RU2016131667A (ru) Состав препарата нейрегулина
JP2013543505A5 (ru)
RU2019100221A (ru) Составы на основе антитела к CD19
RU2010131179A (ru) Жидкая композиция, содержащая антитело высокой концентрации
US20140023655A1 (en) Formulations with reduced viscosity
RU2017101667A (ru) Фармацевтические композиции
JP2019512012A5 (ru)
HRP20220011T1 (hr) Nova stabilna formulacija za fxia protutijela
MX2022004146A (es) Composición farmacéutica de vector de virus adenoasociado y métodos.

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20201216